Investigational drug · Phase 3
GB-0895
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Severe Asthma.
Phase 3Last checked: Nov 19, 2026Latest source record: Nov 17, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
3
Any phase or sponsor naming "GB-0895"
First trial start
2025
Dec 3, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "GB-0895", any sponsor or status.
Conditions studied
As listed on its trial records.
- Severe Asthma
Approved drugs for the same conditions: Asthma · Respiratory
Largest trials
Live from ClinicalTrials.gov: studies naming "GB-0895" as an intervention, largest first.
- A Study to Investigate GB-0895 Adjunctive Therapy in Adults and Adolescents With Severe Uncontrolled Asthma (SOLAIRIA-2)Pivotal-lookingRecruiting
Generate BiomedicinesIndustry
NCT07359846 · 786 participants (planned) · Start Jan 20, 2026 · Primary completion Jan 2029
Drug: GB-0895; Placebo · For: Severe Asthma
Sites: Bakersfield, California; Inglewood, California; Lancaster, California · 166 sites in all
- A Study to Investigate GB-0895 Adjunctive Therapy in Adults and Adolescents With Severe Uncontrolled Asthma (SOLAIRIA-1)Pivotal-lookingRecruiting
Generate BiomedicinesIndustry
NCT07276724 · 786 participants (planned) · Start Dec 3, 2025 · Primary completion Dec 2028
Drug: GB-0895; Placebo · For: Severe Asthma
Sites: Northridge, California; Pasadena, California; Rancho Cucamonga, California · 158 sites in all
- A Study to Investigate GB-0895 in Adults With Mild to Moderate Asthma or COPDPivotal-lookingActive, not recruiting
Generate BiomedicinesIndustry
NCT07116889 · 156 participants (planned) · Start Dec 12, 2023 · Primary completion May 2027
Drug: GB-0895 (SC); GB-0895 (SC) and 2 more · For: Asthma; COPD (Chronic Obstructive Pulmonary Disease)
Sites: DeLand, Florida; Miami, Florida; Orlando, Florida · 13 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Lessons learned from clinical trials of thymic stromal lymphopoietin inhibition.
Corren J, Borish L, Brightling C, et al. · J Allergy Clin Immunol 2026
Also in development for Severe Asthma
- TQC2731Phase 35 trials
Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd. · Asthma, Chronic Obstructive Pulmonary Disease, Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)
- VerekitugUPB-101Phase 24 trials
Upstream Bio Inc. · Severe Asthma, Chronic Obstructive Pulmonary Disease, Chronic Rhinosinusitis With Nasal Polyps
- FB704APhase 21 trial
Oneness Biotech Co., Ltd. · Severe Asthma
- FrevecitinibPhase 21 trial
Kinaset Therapeutics Inc · Severe Asthma
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.